Arnigen 97 mg+103 mg (Tablet)
Unit Price: ৳ 120.00 (2 x 10: ৳ 2,400.00)
Strip Price: ৳ 1,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | General pharmaceuticals ltd |
| Also available as |
Indications
- Reduce the risk of cardiovascular death
- Reduce hospitalization for heart failure
- Treatment of symptomatic heart failure
- Exclusively for pediatric patients aged one year and older
- Administered in conjunction with other heart failure therapies
Pharmacology
- Contains neprilysin inhibitor (sacubitril)
- Contains angiotensin receptor blocker (valsartan)
- Inhibits neprilysin via LBQ657
- Blocks the angiotensin II type-1 receptor via valsartan
- Increases levels of peptides degraded by neprilysin
Dosage & Administration
- Recommended starting dose for adult heart failure
- Titration for pediatric patients based on weight
- Dose adjustment for patients not taking ACE inhibitor or ARB
- Dose adjustment for patients with severe renal impairment
- Dose adjustment for patients with moderate hepatic impairment
Interaction
- Dual blockade of the Renin-Angiotensin-Aldosterone System
- Avoid use with ACE inhibitors
- Increased risk of renal impairment with NSAIDs
- Increased risk of lithium toxicity
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors
- Concomitant use of aliskiren in diabetes patients
Side Effects
- Angioedema
- Hypotension
- Impaired renal function
- Hyperkalemia
- Cough
- Dizziness
Pregnancy & Lactation
- Safety and effectiveness in pediatric patients under 1 year
- No relevant pharmacokinetic differences in elderly patients
- No dose adjustment for mild hepatic impairment
- Not recommended in severe hepatic impairment
- No dose adjustment required in mild to moderate renal impairment
Precautions & Warnings
- May cause angioedema
- Not recommended in patients with known history of angioedema
- May lower blood pressure and cause symptomatic hypotension
- Monitor serum potassium periodically
- Dosage reduction or interruption may be required
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences in elderly patients
- Dose adjustments for severe renal impairment
- Dose adjustments for moderate hepatic impairment
Overdose Effects
- Hypotension likely as a result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis due to high protein binding
Storage Conditions
- Store below 30°C
- Keep in a dry place
- Protect from moisture
- Keep out of the reach of children